Drugmakers’ plan: Sell tomorrow to shore up yesterday

A wave of announced and expected divestitures is sweeping the pharmaceutical industry. Most recently, Pfizer announced an agreement to sell its $1 billion (revenue) drug-delivery technology group Capsugel for $2.4 billion to private equity group Kohlberg Kravis Roberts (KKR). Analysts have speculate...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Seed Health raises $40 million Series A for its synbiotic product

News Commentary | May 05, 2021

This Series A round was led by The Craftory, Artis Ventures, and Gisev. With this funding, the company is looking to expand its consumer health supplement globally as well as focus on clinical research and its digital health unit, following its recent acquisition of Auggi. Seed's therapeutic arm has... Not part of subscription

Pear Therapeutics goes public in SPAC deal

News Commentary | June 30, 2021

The $1.6 billion deal will make Pear Therapeutics (now Pear Holdings Corp.) one of the first digital therapeutics companies to go public. The SPAC merger will allow Pear to go on with commercialization and expansion plans that have struggled since the relationship with Novartis Pharmaceuticals ... To read more, click here.

Will Ginkgo-backed Arcaea "regenerate" the beauty industry with its $78 million Series A?

News Commentary | October 28, 2021

Arcaea is looking to answer what is possible for beauty by leveraging biotech to grow novel ingredients and create supply chains that don't rely on petrochemicals or scarce resources. So far, the company seems to have the means and partnerships to achieve its goals. It has a strong lineup of ... Not part of subscription